Term
|
Definition
|
|
Term
| Generic name for Cytarabine |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Cistracurium |
|
Definition
|
|
Term
| Brand name for Desflurane |
|
Definition
|
|
Term
| Brand Name for Cytarabine |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Glycopyrrolate |
|
Definition
|
|
Term
|
Definition
| Hydrocortisone Acetate and Pramoxine HCl |
|
|
Term
| Brand name for Hydrocortisone Acetate and Pramoxine HCl |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Ifosfamide |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Isoflurane |
|
Definition
|
|
Term
| Generic name for Xylocaine |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Generic name for Brevital |
|
Definition
|
|
Term
| Brand name for Methohexital |
|
Definition
|
|
Term
| Generic name for Papaverine |
|
Definition
|
|
Term
| Brand name for Papaverine |
|
Definition
|
|
Term
| Generic name for Diprivan |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Ropivacaine |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Sevoflurane |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Sodium Hyaluronate |
|
Definition
|
|
Term
| Generic name for Acectine |
|
Definition
|
|
Term
| Brand name for Succinylcholine Chloride |
|
Definition
|
|
Term
| Generic name for Thrombin-JMI |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Generic name for Norcuron |
|
Definition
|
|
Term
| Brand name for Vecuronium |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name for Vincristine Sulfate |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Brand name of Rocuronium Bromide |
|
Definition
|
|
Term
| Indication for Nimbex/Cistracurium |
|
Definition
| Neuromuscular blockade as adjunct to GA for tracheal intubation/mechanical vent |
|
|
Term
| Nimbex/Cisatracurium Strength, formulation and route |
|
Definition
| 2mg/ml as 5 and 10ml vials for injection |
|
|
Term
| Nimbex/Cisatracurium dosing (initial and maintenance) |
|
Definition
| initial: 0.15-0.20mg/kg maintenance: 0.3mg/kg |
|
|
Term
| Nimbex/Cisatracurium drug inteactions |
|
Definition
| Aminoglycosides, tetracyclines, bacitracin, polymixins, lincomycin, clindamycin, colistin, Mg salts, litium, local anesthetics, procainamide, quinidine, colistemethate |
|
|
Term
| Nimbex/Cisatracurium Side effects |
|
Definition
| bradycardia, hypotension, flushing, bronchospasm, rash |
|
|
Term
|
Definition
| acute non-lymphocytic leukemia and blast phase of chronic myelocytic leukemia |
|
|
Term
| How is Cytarabine supplied/form/route |
|
Definition
| 100mg, 500mg, 1g, 2g vials for injection |
|
|
Term
|
Definition
| 100mg/m2/day by continuous IV infusion or q12h |
|
|
Term
| Cytarabine drug interactions |
|
Definition
| Digoxin, cyclophospharmide, vincristine, prednisone, cytarabine, procarbazine |
|
|
Term
|
Definition
| anorexia, nausea, vomiting, diarrhea, hepatic dyfxn, fever rash, thromboflebitis |
|
|
Term
|
Definition
| Bone marrow suppression, leukopenia, thrombocytopenia, anemia. Oral ulceration, hypatic dysfxn |
|
|
Term
|
Definition
|
|
Term
| Suprane/Desflurane dosing |
|
Definition
| admin via vaporizer ONLY! Initial: 0.5-3% increasing by 0.5-1% every 2-3 breaths until onset of anesthesia |
|
|
Term
| Suprane/Desflurane side effects |
|
Definition
| hyperthermia, apnea, breath-holding, caoughing, excitement/struggling, increased secretion, laryngospasm, oxyhemoglobin desaturation, pharyngitis |
|
|
Term
| Suprane/Desflurane drug interactions |
|
Definition
| Aminoglycosides, bacitracin, capreomycin, citrate-anticoag blood, clingamycin, colistimethate, colistin, lidocaine, lincomysin, neuromuscular blocades, polymixins, procaine, tetracyclines, trimethaphan, amiodarone, antihypertensives, diuretics, antimyasthenics, betablockers |
|
|
Term
| Vepesid/Etoposide indication |
|
Definition
| Small cell cancer and refractory testicular tumors |
|
|
Term
| Vepesid/Etoposide supply/formulation/route |
|
Definition
| 20mg/ml concentration for IV injection as 100/5,500/25,1gm/50ml multi-dose vials |
|
|
Term
|
Definition
Testicular CA: 50-100mg/m2/day for 5 days
Small cell lung CA: 35-50mg/m2/day for 5 days. Repeated on 3-4wk intervals |
|
|
Term
| Vepesid/Etoposide warnings |
|
Definition
| Mylosupression involving bone marrow (dose limiting) |
|
|
Term
| Vepesid/Etoposide side effects |
|
Definition
|
|
Term
| Robinul/Glycopyrrolate indication |
|
Definition
|
|
Term
| Robinul/Glycopyrrolate supply/form/route |
|
Definition
| 1mg and 2mg tablets via oral route |
|
|
Term
| Robinul/Glycopyrrolate dosing |
|
Definition
| Varies from patient to patient. Max daily dose of 8mg |
|
|
Term
| Robinul/Glycopyrrolate contraindications |
|
Definition
| Glaucoma, obstructive uropathy, atony of the elderly, unstable cardiovascular, myesthenia gravis and ulcerative colitis |
|
|
Term
| Robinul/Glycopyrrolate warning |
|
Definition
| avoid with high temperature, stroke can occure. |
|
|
Term
| Robinul/Glycopyrrolate side effects |
|
Definition
| CNS effects: drowsiness, neuromuscular blockade, muscular weakness, paralysis |
|
|
Term
| Epifoam/Hydrocortisone with Pramoxine indication |
|
Definition
| hemorrhoids, anal fissures, dermatitis, psoriasis |
|
|
Term
| Epifoam/Hydrocortisone with Pramoxine supply/formulation/route |
|
Definition
| 10g pressurized aerosol topical foam 1%-hyrdocortisone 1%-pramoxine |
|
|
Term
| Epifoam/Hydrocortisone with Pramoxine dosing |
|
Definition
| Apply to affected are TID-QID |
|
|
Term
| Epifoam/Hydrocortisone with Pramoxine side effects |
|
Definition
| Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic dermatitis, maceration of skin, secondary infxn, skin atrophy, striae, millaria |
|
|
Term
| Ifex/Ifosamide indication |
|
Definition
| 3rd line for germ cell testicular cancer |
|
|
Term
| Ifex/Ifosfamide supply/formulation/route |
|
Definition
| 1g and 3g single dose vials for injection |
|
|
Term
|
Definition
| 1.2g/m2/day for 5 days. Repeat q3wk |
|
|
Term
| Ifex/Ifosfamide contraindications |
|
Definition
| Patients with severely depressed bone marrow fxn |
|
|
Term
| Ifex/Ifosfamide side effects |
|
Definition
| Alopecia (83%), N/V, hematuria, CNS toxicity, infxn |
|
|
Term
| Ifex/Ifosfamide box warning |
|
Definition
| Urotoxic side effects (Hemorrhagic cystitis) and CNS toxicity such as coma |
|
|
Term
| Xylocaine/Lidocane indication |
|
Definition
| Local or regional anesthesia |
|
|
Term
| Xylocaine/Lidocane supply/formulation/route |
|
Definition
0.5% (5mg/ml)as 50ml
1% (10mg/ml) as 2,3,40ml vials
1.5% (15mg/ml) as 20ml vial
2% (20mg/ml) as 2, 5, 10ml vials
4% (40mg/ml) as 5ml vial for injection |
|
|
Term
| Xylocaine/Lidocane dosing |
|
Definition
| For IV only use 0.5% 50ml SDV max dose of 4.5mg/kg/dose Do not exceed 300mg |
|
|
Term
| Xylocaine/Lidocane contraindication |
|
Definition
| Hypersensitivity to amide local anesthetics |
|
|
Term
| Xylocaine/Lidocane drug interactions |
|
Definition
| MAOI, tricyclic antidepressants, phenothiazines, butyrophenones |
|
|
Term
| Xylocaine/Lidocane side effects |
|
Definition
| Drowsiness, dizziness, euphoria, confusion, resp depression, blurred/double vision, vomiting |
|
|
Term
| Brevital/Methohexital indications |
|
Definition
| Induction of general anesthetic |
|
|
Term
| Brevital/Methohexital supply/formulation/route |
|
Definition
| 500mg/50ml vial, 2.5g/50ml vial for injection |
|
|
Term
| Brevital/Methohexital dose |
|
Definition
Induction: 1-1.5mg/kg IV
Maint: about 20-40mg q4-7min |
|
|
Term
| Brevital/Methohexital contraintications |
|
Definition
| Latent/manifest porphyria, barbiturate hypersensitivety |
|
|
Term
| Brevital/Methohexital drug interactions |
|
Definition
| Phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, propylene glycol containing solutions |
|
|
Term
| Brevital/Methohexital side effects |
|
Definition
| hypotension, tachycardia, respiratory depression, nausea, abd pain |
|
|
Term
|
Definition
Cerebral and peripheral ischemia from arterial spasm
Myocardial ischemia w/ arrythmia
Erectile dyfxn w/ or w/o phentolamine
Acute vascular occlusion w/ anticoag |
|
|
Term
| Papaverine supply/formulation/route |
|
Definition
150mg ER cap
30mg/ml MDV or preservative free as SDV |
|
|
Term
| Papaverine dose: Cardio/vascular, ED, Oral |
|
Definition
C/V: 30mg IV or IM every 3 hours
ED: 2.4-37.5mg Intracavernosal
PO: 150mg q8-12h or 300mg q12h |
|
|
Term
| Papaverine contraindications |
|
Definition
|
|
Term
| Papaverine drug interactions |
|
Definition
| CNS depressants, levodopa, morphine |
|
|
Term
|
Definition
N/D/C, tachycardia, anorexia, abd distress, malaise, drowsiness, vertigoo, sweating, HA, rash, flushing,sedation, hepatitis, hypo/hypertension, thrombosis @ inj site
Intracavernosal: priapism, pain, burning, paresthesia |
|
|
Term
| Diprivan/Propofol indication |
|
Definition
| Induction and maintenance of anesthesia |
|
|
Term
| Diprivan/Propofol supply/formulation/route |
|
Definition
| 10mg/ml concentration in 10, 50, 100ml vial for infusion |
|
|
Term
|
Definition
Individualized
Begin at 0.3mg/kg/hr inc by 0.3-0.6mg/kg/hr until desired sedation
Maint: 0.3-3mg/kg/hr (5-50ug/kg/min) |
|
|
Term
| Diprivan/Propofol drug interactions |
|
Definition
| Morphine, meperidine, fentanyl, benzos, barbiturates,chloral hydrate, droperidol, opioids, nitrous oxide |
|
|
Term
| Diprivan/Propofol side effects |
|
Definition
| Brady/tachycardia, arrythmia, hypotension, burning at inj site, apnea, rash, puritis |
|
|
Term
| Naropin/Ropivacaine indication |
|
Definition
| Epidural block for surgery, cesarean, acute pain, labor |
|
|
Term
| Naropin/Ropivacaine supply/formulation/route |
|
Definition
| 2,5,7.5,10mg/ml for injection |
|
|
Term
| Naropin/Ropivacaine dosing |
|
Definition
Surgical:5-10mg/ml
Labor: 2mg/ml
Post-op: 2-5mg/ml
Max 770mg/24h |
|
|
Term
| Naropin/Ropivavaine contraindications |
|
Definition
| Hypersensitivity to amide anesthetics |
|
|
Term
| Naropin/Ropivacaine drug interactions |
|
Definition
| Fluvoxamine, amiodarone, ibutilide, sotalol, dofetilide, dronedarone, and CYP1A2 inhibitors |
|
|
Term
| Naropin/Ropivacaine side effects |
|
Definition
| N/V, hypotension, bradycardia, HA, paresthesia, pain, puritis, fever, chills, DZ, hypoesthesia, urinary retention, failed progression of labor, anxiety, rhinitis |
|
|
Term
| Anectine/Succinylcholine indication |
|
Definition
| Neuromuscular blockade and aid in intubation (ultra short acting skeletal muscle relaxant) |
|
|
Term
| Anectine/Succinylcholine supply/formulation/route |
|
Definition
| 20mg/ml concentration in 10ml vials for IV injection |
|
|
Term
| Anectine/succinylcholine dose |
|
Definition
Short procedure: 0.6mg/kg
Long procedure: 2.5-4.3mg/min |
|
|
Term
| Anectine/Succinylcholine contraindications |
|
Definition
| malignant hyperthermia, skeletal muscle myopathies, acute phase of injury (burns, trauma, skeletal muscle, neuron) |
|
|
Term
| Anectine/Succinylcholine drug interactions |
|
Definition
| promazine, oxytocin, aprotinin, quinidine, beta blockers, procainamide, lidocain, trimethaphan, lithium, Mg salts, quinine, chloroquine, diethylether, isoflurane, desflurane, metoclopramide, terbutaline |
|
|
Term
| Anectine/Succinylcholine side effects |
|
Definition
| Cardiac arrest, malignant hyperthermia, arrythmia, brady/tachycardia, hyper/hypotension, hyperkalemia, resp depression/apnea |
|
|
Term
| Anectine/Succinylcholine box warning |
|
Definition
| Risk of cardiac arrest from hyperkalemic rhabdomyolysis |
|
|
Term
| Thrombin supply/formulation/dose |
|
Definition
5,000IU; 20,000IU; Vial
20,000IU nasal spray
20,000IU syringe kit
5,000IU epistaxis kit |
|
|
Term
|
Definition
| hemostasis w/ minor bleeding from capillaries and small venules |
|
|
Term
|
Definition
apply 1,000-2,000IU/ml solution to area of bleed
Percutaneous: 100-1000IU/ml 0.3-3ml |
|
|
Term
| Thrombin contraindications |
|
Definition
|
|
Term
|
Definition
| Altered PT (prothrombin time)and PTT (partial thromboplastin time), severe bleeding |
|
|
Term
| Norcuron/Vecuronium indication |
|
Definition
| adjunct to GA. Neuromuscular block, tracheal intubation |
|
|
Term
| Norcuron/Vecuronium supply/formulation/route |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Norcuron/Vecuronium drug interactions |
|
Definition
| succinylcholine, inhaled anesthetics, aminoglycosides, tetracyclines, bacitracin, tiopental |
|
|
Term
| Norcuron/Vecuronium side effects |
|
Definition
| Drug action longer than needed causing weakness, prolonged muscle paralysis, resp insufficiency, apnea |
|
|
Term
| Oncovin/Vincristine indication |
|
Definition
| Leukemia or in combo therapy for Hodgkins, Non-Hodgekins, rhabdomyosarcoma, neuroblastoma, Wilms tumor |
|
|
Term
| Oncovin/Vincristine supply/formulation/route |
|
Definition
| 1mg/ml concentration as 1 and 2ml vials *keep refridgerated and protect from light |
|
|
Term
|
Definition
|
|
Term
| Oncovin/Vincristine contraindications |
|
Definition
| Demyelinating Charot-Marie-Tooth syndrome |
|
|
Term
| Oncovin/Vincristine drug interactions |
|
Definition
Do not mix w/ solutions that change pH outside range of 3.5-5.5
Do not mix with anything other than NS or glucose in water |
|
|
Term
| Oncovin/Vincristine side effects |
|
Definition
Neuromuscular: loss of tendon relfex, foot drop, ataxia, paralysis, jaw pain, pharyngeal pain
GI: constipation, abd cramp, wt loss
Genitourinary: polyuria, dysuria, urinary retention
Cardio: hyper/hypotension
Fever and HA |
|
|
Term
| Oncovin/Vincristine box warning |
|
Definition
Fatal if given intrathecially, Extravasion must DC dose and inject remainder in another vein
Cellulitis |
|
|
Term
| Zemuron/Rocuronium indication |
|
Definition
| Adjunct to GA for intubation/mechanical vent |
|
|
Term
| Zemuron/Rocuronium supply/form/dose |
|
Definition
| 10mg/ml concentration as 50mg/5ml or 100mg/10ml MDV for injection |
|
|
Term
|
Definition
Induction: 0.6-1.2mg/kg
Maint: 10-12mcg/kg/min |
|
|
Term
| Zemuron/Rocuronium drug interactions |
|
Definition
Anasthetics, aminoglycosides, vancomycin, tetracyclines, bacitracin, polymixins, colistin, colistimethate, quinidine, Mg, lithium, procainamide cause ENHANCED Zemuron
Anticonvulsants cause DECREASED Zemuron |
|
|
Term
|
Definition
| Cytarabine, Vepesid/Etoposide, Ifex/Ifosfamide, Oncovin/Vincristine |
|
|
Term
| Drugs indicated for testicular cancer |
|
Definition
| Vepesid/Etoposide and Ifex/Ifosfamide |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Nimbex, Anectine, Norcuron, Zemuron |
|
|
Term
| Indicated for induction of GA |
|
Definition
| Forane, Brevital, Diprovan, Ultane |
|
|
Term
| Which drugs do not have any drug interactions |
|
Definition
| Vepesid, Robinul, Epifoam, Ifex, Thrombin |
|
|
Term
|
Definition
|
|
Term
| Brand name for Sevoflurane |
|
Definition
|
|
Term
| Indication for Ultane/Sevoflurane |
|
Definition
|
|
Term
| Ultane/Sevoflurane strength/formulation/route |
|
Definition
| 250ml vials of volatile sevoflurane for ihalation |
|
|
Term
| Ultane/Sevoflurane dosing |
|
Definition
| individualized for pt depending on respsone, delivered via vaporizer |
|
|
Term
| Ultane/Sevoflurane contraindications |
|
Definition
| susceptibility to malignant hyperthermia or halogenated hypersensitivity |
|
|
Term
| Ultane/Sevoflurane drug interactions |
|
Definition
Compatible w/ IV anesthetics!
Nitrous oxide interation, neuromuscular blockade interaction (pancuronium, vecuronium, atracurium) |
|
|
Term
| Ultane/Sevoflurane side effects |
|
Definition
| Brady/tachycardia, hypotension, laryngospasm, airway obstruction, cough, breath holding, seizures |
|
|
Term
|
Definition
|
|
Term
| Brand name for Sodium Hyaluronate |
|
Definition
|
|
Term
| Indication for Hyalgan/Sodium Hyaluronate |
|
Definition
| Osteoartheritis for pt failing non-pharmacologic therapy and APAP |
|
|
Term
| Hyalgan/Sodium Hyaluronate Strength/Formulation/Route |
|
Definition
| 20mg/2ml vial or prefilled syringe for intra-articular injection |
|
|
Term
| Hyalgan/Sodium Hyaluronate dose |
|
Definition
|
|
Term
| Hyalgan/Sodium Hyaluronate contraindications |
|
Definition
| injection site/sking infection/disease |
|
|
Term
| Hyalgan/Sodium Hyaluronate drug interactions |
|
Definition
| Disinfectants w/ quaternary ammonium salts |
|
|
Term
| Hyalgan/Sodium Hyaluronate side effects |
|
Definition
| GI, inj site pain, swelling/effusion, local rxn (rash etc), puritus, HA |
|
|
